Skip to main content
SRZN
NASDAQ Life Sciences

Major Investor Group, Including Director, Boosts Stake in Surrozen with $6M in Recent Stock Purchases

Analisis de IA por Wiseek
Sentimiento info
Positivo
Importancia info
9
Precio
$20.25
Cap. de mercado
$171.386M
Min. 52 sem.
$5.9
Max. 52 sem.
$24.94
Market data snapshot near publication time

summarizeResumen

The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.


check_boxEventos clave

  • Significant Insider Buying

    The Column Group, a major institutional investor, reported approximately $6.0 million in stock purchases between November 2025 and January 2026.

  • Increased Beneficial Ownership

    The purchases, made by affiliated funds, represent a substantial increase in their stake, now totaling 35.1% of the company's common stock for individuals Tim Kutzkey (a director) and Peter Svennilson.

  • Director Confidence

    Tim Kutzkey, a member of Surrozen's board of directors, is part of the reporting group, signaling strong insider confidence.

  • Material Investment

    The aggregated purchases amount to approximately 3.5% of Surrozen's market capitalization, indicating a material commitment from a key investor.


auto_awesomeAnalisis

The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.

En el momento de esta presentación, SRZN cotizaba a 20,25 $ en NASDAQ dentro del sector Life Sciences, con una capitalización de mercado de aproximadamente 171,4 M$. El rango de cotización de 52 semanas fue de 5,90 $ a 24,94 $. Este documento fue evaluado con un sentimiento de mercado positivo y una puntuación de importancia de 9 sobre 10.

descriptionVer presentacion principal de la SEC

show_chartGrafico de precios

Compartir este articulo

Copied!

feed SRZN - Ultimos analisis

SRZN
Mar 30, 2026, 6:21 PM EDT
Filing Type: 424B5
Importance Score:
7
SRZN
Mar 25, 2026, 8:02 PM EDT
Filing Type: 4
Importance Score:
8
SRZN
Mar 23, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
9
SRZN
Mar 23, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
SRZN
Mar 23, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
SRZN
Mar 23, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
SRZN
Mar 16, 2026, 7:05 PM EDT
Filing Type: 4
Importance Score:
7
SRZN
Jan 22, 2026, 6:55 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
SRZN
Jan 20, 2026, 7:35 PM EST
Filing Type: 4
Importance Score:
7
SRZN
Jan 08, 2026, 5:19 PM EST
Filing Type: 4
Importance Score:
7